SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol

Collapse authors list.
McCarthy, Caroline, Sacco, Joseph, Fedele, Stefano, Ho, Michael, Porter, Stephen, Liloglou, Triantafillos ORCID: 0000-0003-0460-1404, Greenhalf, Bill, Robinson, Max, Young, Bridget ORCID: 0000-0001-6041-9901, Cicconi, Silvia et al (show 5 more authors) , Chauhan, Seema, Tesfaye, Binyam, Jackson, Richard, Sherratt, Frances ORCID: 0000-0003-4147-9305 and Shaw, Richard ORCID: 0000-0002-5157-4042 (2021) SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol. TRIALS, 22 (1).

Text SAVER trial protocol paper.pdf - OA Published Version Download (1MB) | Preview

Item Type:	Article
Uncontrolled Keywords:	Oral epithelial dysplasia, Sodium valproate, Epigenetic reprogramming, Drug repurposing, Randomised controlled trial, Chemoprevention
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Population Health Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	15 Jul 2021 09:10
Last Modified:	11 Nov 2021 13:10
DOI:	10.1186/s13063-021-05373-8
Open Access URL:	https://trialsjournal.biomedcentral.com/articles/1...
Related URLs:	Author
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3130119

Available Versions of this Item

• SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol. (deposited 08 Jul 2021 10:42)
  • SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol. (deposited 15 Jul 2021 09:10) [Currently Displayed]